Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DMQ
|
|||
| Former ID |
DIB010695
|
|||
| Drug Name |
Fabesetron
|
|||
| Synonyms |
FK-1052
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58; ICD-9: 564.1, 787.91] | Discontinued in Phase 2 | [1] | |
| Company |
Fujisawa Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H19N3O
|
|||
| Canonical SMILES |
CC1=C2CCC(C(=O)N2C3=CC=CC=C13)CC4=C(NC=N4)C
|
|||
| InChI |
1S/C18H19N3O/c1-11-14-5-3-4-6-17(14)21-16(11)8-7-13(18(21)22)9-15-12(2)19-10-20-15/h3-6,10,13H,7-9H2,1-2H3,(H,19,20)/t13-/m1/s1
|
|||
| InChIKey |
AEKQMJRJRAHOAP-CYBMUJFWSA-N
|
|||
| CAS Number |
CAS 129300-27-2
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:31588
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Modulator | [2] |
| 5-HT 4 receptor (HTR4) | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT4 type receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | |||
| Reactome | Serotonin receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001434) | |||
| REF 2 | Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.